Clinicopathologic Conference, Amyotrophic Lateral Sclerosis
NEJM 380:1566-1574, Case 12-2019, 2019
Diagnosis and Management of Motor Neurone Disease
BMJ 336:658-662, McDermott,C.J. &Shaw,P.J., 2008
Lead Poisoning From the Beauty Case: Neurologic Manifestations in an Elderly Woman
Neurol 69:929-930, Fluri,F.,et al, 2007
Clinicopath Conf., Multifocal Motor Neuropathy With Conduction Block
NEJM 357: 2707-2715, Case 40-2007, 2007
Clinicopath Conf
Motor Neuron Disease, Progressive-Muscular-Atrophy Type, Case 43-1992, NEJM 327:1298-130592., , 1992
Neuromuscular Disease in Primary Hyperparathyroidism
Ann Int Med 80:182, Patten,B.M.,et al, 1974
Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
Progressive Proximal Weakness in a 56-year-old Man with Bone Pain
Neurol 93:939-944, Torabi,T.,et al, 2019
Clinicopathologic Conference, Intracranial Hypertension Associated with Systemic Lupus Erythematosus and Steroid Use
NEJM 378:282-289, Case 2-2018, 2018
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Clinicopath Conf., Endheim-Chester Disease
NEJM 359:736-747, Case 25-2008, 2008
Premenstrual Multiple Sclerosis Pseudoexacerbations: Role of Body Temperature and Prevention With Aspirin
Arch Neurol 63:1005-1008, Wingerchuk,D.M. &Rodriguez,M., 2006
Modafinil for Fatigue in MS
Neurol 64:1139-1143, Stankoff,B.,et al, 2005
Randomized Controlled Trial of Yoga and Exercise in Multiple Sclerosis
Neurol 62:2058-2064, Oken,B.S.,et al, 2004
Clinicopath Conf, Primary Lymphoma of CNS
NEJM 346:1009-1015, Case 10-2002, 2002
Efficacy and Safety of Modafinil (Provigil) for the Treatment of Fatigue in Multiple Sclerosis: A Two Centre Phase 2 Study
JNNP 72:179-183,150, Rammohan,K.W.,et al, 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Impact of Aerobic Training on Fitness and Quality of Life in Multiple Sclerosis
Ann Neurol 39:432-441, 4221996., Petajan,J.H.,et al, 1996
Fatigue Therapy in Multiple Sclerosis:A Double-blind, Randomized, Parallel Trial of Amantadine, Pemoline & Placebo
Neurol 45:1956-1961, Krupp,L.B.,et al, 1995
A Chronic Illness of Fatigue, Neurologic and Immunologic Disorders, & Active Human Herpesvirus Type 6 Infection
Ann Int Med 116:103-113, Buchwald,D.,et al, 1992
Nervous System Lyme Borreliosis-Revisited
Arch Neurol 49:102-107, Finkel,M.J.&Halperin,J.J., 1992
A Double-Blind, Renadomized, Crossover Trial of Pemoline in Fatigue Assoc with Multiple Sclerosis
Neurol 42:1468-1471, Weinshenker,B.G.,et al, 1992
"Fatigue"in Patients with Multiple Sclerosis
Arch Neurol 49:517-524, Sandroni,P.,et al, 1992
Late Effects of Paralytic Poliomyelitis in Olmsted County, Minnesota
Neurol 41:501-507, Windebank,A.J.,et al, 1991
Excessive Muscular Fatigue in Patients with Spastic Paraparesis
Neurol 40:1271-1274, Miller,R.G.,et al, 1990
Amantadine Treatment of Fatigue Associated with Multiple Sclerosis
Arch Neurol 46:676-680, Cohen,R.A.&Fisher,M., 1989
Demyelinating Diseases
In Rowlands Merritt's Textbk of Neurology, Lea & Febiger, Phila, 8th Ed, p. 749, Sibley,W.A.,et al, 1989
Fatigue in Multiple Sclerosis
Arch Neurol 45:435-437, Krupp,L.B.,et al, 1988
Amantadine, Fatigue, and Multiple Sclerosis
Arch Neurol 45:1104-1106, Rosenberg,G.A.&Appenzeller,O., 1988